TrialJournal for immunotherapy of cancer2020

Results of a randomized, double-blind phase II clinical trial of NY-ESO-1 vaccine with ISCOMATRIX adjuvant versus ISCOMATRIX alone in participants with high-risk resected melanoma.

Jonathan S Cebon et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.